Press Releases


January 2, 2019
Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data from its HPN424 Phase 1 Trial in Prostate Cancer


December 27, 2018
Harpoon Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

December 2, 2018
Harpoon Therapeutics Presents Preclinical Data Supporting Development of HPN217, a New BCMA-Targeting TriTAC, at the 2018 American Society of Hematology (ASH) Annual Meeting

November 11, 2018
Harpoon Therapeutics Announces Closing of $70M Series C Financing

November 9, 2018
Harpoon Therapeutics Unveils ProTriTAC Platform: A Novel, Protease-Activated T Cell Engager Platform Designed to Access a Broad Landscape of Solid Tumor Targets

October 30, 2018
Harpoon Therapeutics Announces Appointment of Ms. Georgia L. Erbez to Chief Financial Officer and Promotion of Holger Wesche, Ph.D., to Chief Scientific Officer

October 11, 2018
Harpoon Therapeutics Appoints Ms. Julie Eastland, Biotech Industry Veteran, to Board of Directors

October 3, 2018
Harpoon Therapeutics Announces Appointment of Natalie R. Sacks, M.D., as Chief Medical Officer 

September 18, 2018
Harpoon Therapeutics Announces Appointments to Board of Directors and Management Team

August 27, 2018
Harpoon Therapeutics Expands Board of Directors

August 6, 2018
Harpoon Therapeutics Treats First Patient with HPN424 in Phase 1 Clinical Trial of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

June 26, 2018
Immunotherapy Pioneer and Serial Biotech Entrepreneur Patrick Baeuerle to Present Compelling Data from Harpoon Therapeutics’ Biotherapeutics Platform at the 2018 European Congress on Biotechnology

April 16, 2018
Harpoon Therapeutics Launches Immuno-Oncology Pipeline with Compelling Data from Lead Programs at the 2018 American Association for Cancer Research (AACR) Annual Meeting


October 26, 2017
Harpoon Therapeutics Expands Management Team

October 18, 2017
AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration 

May 25, 2017
Harpoon Therapeutics Announces Completion Of $45M Series B Financing

May 4, 2017
Harpoon Therapeutics Appoints Che-Leung Law, Ph.D., as Vice President, Translational Medicine

January 26, 2017
Harpoon Therapeutics Appoints William E. Picht, Jr. as Chief Financial Officer


December 13, 2016
Harpoon Therapeutics Appoints Gerald McMahon, Ph.D., as President and CEO